co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
The company has to rapidly grow its business volumes
While Safari is making the most of the opportunities, VIP remains in a weak spot
Coromandel International and Paradeep Phosphates have multiple value-accretive catalysts.
Piyush Goyal’s proposed meeting with the Tesla boss could not take place, delaying the electric carmaker’s India investment plan
A credible profitability roadmap for pharmacy is the ask
PI Industries, with superior execution and a solid business model, is on track to achieve its long-term strategic objectives
The stock is valued at 60 times estimated FY24 earnings, not significantly lower than United Spirits
Average monthly transacting customers on the food delivery platform rose sequentially for the second consecutive quarter
The thermal capacity awards target has been raised to 11,200 MW from 7,200 MW
India’s share in the global ER&D sourcing market is expected to increase more than three-fold by 2030, says LTTS CEO
High channel inventory, dismal pricing, weak cashflows, high leverage – all came together to hurt the overall business. In fact, a lot of things will have to improve before we could see a reason for any rerating
The company’s US revenues are projected to move closer to $900 million in FY24 and $1 billion in FY25, up from $148 million in FY15
Honasa is trading at a valuation in line with its peers in similar businesses notching up significantly higher margins
Long-term business potential is not affected by near-term headwinds
Industry headwinds and company specific issues can lead to weak performance in the near term
Agrochemicals' revenues plunged in Q2 on steep price erosion in international markets
The near-term outlook is rather weak and doesn’t present an appealing investment opportunity
The bank has multiple levers in place to drive RoA expansion
Despite witnessing a late recovery in September, domestic pharma sales moderated sequentially in Q2, which is likely to put pressure on the July-September earnings of drugmakers
A company with a healthy balance sheet and an R&D-focused parentage, but growth in the exports market will be slow
As FY25 promises to be good, the lowering of guidance for the current fiscal won’t have much impact on stock
Encouraging outlook for second half, traction in margin, and record order inflows augur well for the company
Growth in the Indian pharma market slowed to 7 percent in Q2 of FY24 from 8.5 percent in Q1
Analysts said the race to the bottom seems to be over and there appears to be a clear shift in the sector, with prices increasing gradually
Margins to moderate but growth potential high, given the small size of the company
